Skip to content
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing COVID-19 in people aged 12 years or older. The vaccine was approved in May 2025 by the US FDA for individuals aged 65 years or older or aged 12-64 years …
Read More
2025-12-13
